Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways

Journal of Hepatology

Volumn 57, Issue 3, 2012, Pages 577-583

  Wang, Chunmei ^a   Delogu, Salvatore ^b   Ho, Coral ^a   Lee, Susie A ^a   Gui, Bing ^a   Jiang, Lijie ^a   Ladu, Sara ^c   Cigliano, Antonio ^b   Dombrowski, Frank ^b   Evert, Matthias ^b   Calvisi, Diego F ^b   Chen, Xin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

AKT; HCC; MAPK; PKM2; Spry2

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHENYLALANINE; PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M2; SPROUTY PROTEIN; SPROUTY PROTEIN 2; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GLYCOLYSIS; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TUMOR; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADENOMA; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; PLASMIDS; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVATE KINASE; TRANSFECTION;

EID: 84865153223     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.04.026     Document Type: Article

References (30)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
3. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
4. A. Villanueva, and J.M. Llovet Targeted therapies for hepatocellular carcinoma Gastroenterology 140 2011 1410 1426
5. S. Whittaker, R. Marais, and A.X. Zhu The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene 29 2011 4989 5005
6. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 2007 1261 1274 (Pubitemid 46962095)
7. R. Zoncu, A. Efeyan, and D.M. Sabatini MTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 2011 21 35
8. A. Villanueva, D.Y. Chiang, P. Newell, J. Peix, S. Thung, and C. Alsinet Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
9. D. Ruggero, and N. Sonenberg The Akt of translational control Oncogene 24 2005 7426 7434 (Pubitemid 41637982)
10. D.F. Calvisi, C. Wang, C. Ho, S. Ladu, S.A. Lee, and S. Mattu Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma Gastroenterology 140 2010 1071 1083
11. V.A. Galicia, L. He, H. Dang, G. Kanel, C. Vendryes, and B.A. French Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2 Gastroenterology 139 2010 2170 2182
12. D.F. Calvisi, S. Ladu, A. Gorden, M. Farina, E.A. Conner, and J.S. Lee Ubiquitous activation of Ras and Jak/Stat pathways in human HCC Gastroenterology 130 2006 1117 1128
13. H. Tsuda, S. Hirohashi, Y. Shimosato, Y. Ino, T. Yoshida, and M. Terada Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma Jpn J Cancer Res 80 1989 196 199 (Pubitemid 20027206)
14. C. Challen, K. Guo, J.D. Collier, D. Cavanagh, and M.F. Bassendine Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas J Hepatol 14 1992 342 346
15. F. Edwin, K. Anderson, C. Ying, and T.B. Patel Intermolecular interactions of Sprouty proteins and their implications in development and disease Mol Pharmacol 76 2009 679 691
16. T.L. Lo, C.W. Fong, P. Yusoff, A.B. McKie, M.S. Chua, and H.Y. Leung Sprouty and cancer: the first terms report Cancer Lett 242 2006 141 150 (Pubitemid 44515046)
17. C.W. Fong, M.S. Chua, A.B. McKie, S.H. Ling, V. Mason, and R. Li Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma Cancer Res 66 2006 2048 2058
18. S.A. Lee, C. Ho, R. Roy, C. Kosinski, M.A. Patil, and A.D. Tward Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer Hepatology 47 2008 1200 1210 (Pubitemid 351547906)
19. S.A. Lee, S. Ladu, M. Evert, F. Dombrowski, V. De Murtas, and X. Chen Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis Hepatology 52 2010 506 517
20. C. Ho, C. Wang, S. Mattu, G. Destefanis, S. Ladu, and S. Delogu AKT and N-Ras coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR, FOXM1/SKP2, and c-Myc pathways Hepatology 55 2012 833 845
21. C.M. Carlson, J.L. Frandsen, N. Kirchhof, R.S. McIvor, and D.A. Largaespada Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse Proc Natl Acad Sci USA 102 2005 17059 17064 (Pubitemid 41692683)
22. C.H. Frith, J.M. Ward, and V.S. Turusov Tumours of the liver IARC Sci Publ 1994 223 269
23. P. Xia, S. Wang, Z. Guo, and X. Yao Emperipolesis, entosis and beyond: dance with fate Cell Res 18 2008 705 707 (Pubitemid 351948224)
24. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
25. A.J. Levine, and A.M. Puzio-Kuter The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes Science 330 2010 1340 1344
26. C.J. David, M. Chen, M. Assanah, P. Canoll, and J.L. Manley HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer Nature 463 2010 364 368
27. S. Mazurek Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells Int J Biochem Cell Biol 43 2011 969 980
28. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, and R. Wei The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233 (Pubitemid 351380249)
29. W. Yang, Y. Xia, H. Ji, Y. Zheng, J. Liang, and W. Huang Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation Nature 480 2011 118 122
30. W. Luo, H. Hu, R. Chang, J. Zhong, M. Knabel, and R. O'Meally Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell 145 2011 732 744